Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventive therapy for tuberculosis

B Miller1

  • 1Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.

The Medical Clinics of North America
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are amyotrophic lateral sclerosis patients cognitively normal?

Neurology·2003
Same author

Radiation hybrid map, physical map, and low-pass genomic sequence of the canine prcd region on CFA9 and comparative mapping with the syntenic region on human chromosome 17.

Genomics·2003
Same author

Hypothalamic control of gonadotropin secretion.

Progress in brain research·2003
Same author

The behavioral spectrum of tic disorders: a community-based study.

Neurology·2002
Same author

Early retinal damage in experimental diabetes: electroretinographical and morphological observations.

Experimental eye research·2002
Same author

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

Neurology·2002
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Preventive therapy significantly lowers the risk of developing tuberculosis (TB) in infected individuals. Wider adoption of this therapy is crucial for global TB control and elimination efforts.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Background:

  • Tuberculosis (TB) remains a global health challenge, exacerbated by the HIV epidemic.
  • HIV co-infection significantly increases the risk of developing active TB in infected individuals.
  • Current TB rates are substantially elevated worldwide due to these factors.

Purpose of the Study:

  • To highlight the effectiveness of isoniazid (INH) preventive therapy in reducing clinical TB.
  • To identify barriers hindering the widespread use of TB preventive therapy.
  • To emphasize the importance of screening high-risk individuals and initiating preventive treatment.

Main Methods:

  • Review of existing literature on TB epidemiology and preventive therapy.
  • Analysis of factors contributing to low uptake of preventive therapy, including healthcare professional knowledge, patient adherence, and drug toxicity.

Related Experiment Videos

  • Discussion of current research into novel, shorter preventive regimens and drug delivery systems.

    • Main Results:

    • Isoniazid (INH) preventive therapy, administered for 6-12 months, substantially reduces the risk of developing clinical TB.
    • Key barriers to effective TB prevention include insufficient healthcare provider knowledge, patient nonadherence, and adverse drug effects.
    • Newer, shorter-duration regimens and innovative drug delivery methods are under investigation.

    Conclusions:

    • Preventive therapy is a critical tool for reducing TB incidence in infected populations.
    • Addressing barriers related to knowledge, adherence, and toxicity is essential for successful TB control.
    • Widespread implementation of preventive therapy is necessary to achieve global TB control and elimination goals.